Background: Meningiomas are extra-axial primary neoplasms that frequently arise from arachnoid cap cells. Meningiomas account for around 33% of all primary brain tumours. Objective:The aim of the present study was to compare relationship between different grades of meningiomas and clinicopathological character, treatment and its outcome. Patients and methods: This is a retrospective study included 52 adult meningioma patients treated at Clinical Oncology Department of Zagazig University Hospitals. The study included data of clinicopathological characters, grades of meningioma treatment and its outcome. Results: Among the studied patients, grade I meningioma was more common than grade II and III. The most common site of meningioma was convexity and sphenoid ring. Spinal meningioma accounted for 1.9%. The most common pathological type of meningioma was meningothelial meningioma, transitional and anaplastic. Size of tumor at initial diagnosis was less than 5 cm in 59.5%. Surgical resection was done in all grades of meningioma in 47 patients (90.4%). 33 patients received postoperative radiotherapy (63.5%) and 13 patients were on follow up after surgery (25%). Dose of radiotherapy differed according to grade of meningioma whereas in grade I radiotherapy dose used was (54-55Gy) in 40.5% of patients and dose of 60 Gy was used in patients of grade II and III (42.9% and 75% respectively). Conclusion: Tumor grade was the most important prognostic factor in meningioma patients who received radiation therapy. In patients with grade II and III tumors the extent of surgical resection was significantly associated with over all survive.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.